-J A Meyerhardt Researcher Activity Profile

Research Author Detailed Information 

J A Meyerhardt Publication Rate By Year

J A Meyerhardt has published 2 paper(s) in 2006, 12 paper(s) in 2007, 5 paper(s) in 2008, for a total of 19 research publications in total.

J A Ja Meyerhardt Author Information

LAST NAME: meyerhardt

FIRST NAME: J A

INITIALS: ja

AFFILIATION:

Papers

J A Meyerhardt's Publication Record

1. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
2. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
3. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
4. Hormone replacement therapy and survival after colorectal cancer diagnosis. Year Published: 2006
Dana-Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA. jang@partners.org
5. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Year Published: 2006
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA. azhu@partners.org
6. Adjuvant and neoadjuvant approaches in gastric cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. kng4@partners.org
7. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Year Published: 2007
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. azhu@partners.org
8. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
9. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. jmeyerhardt@partners.org
10. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
11. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
12. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis St, BWH Pathology, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
13. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Year Published: 2007
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. azhu@partners.org
14. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
15. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
16. Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA, 02115, USA, jmeyerhardt@partners.org.
17. Adjuvant and neoadjuvant approaches in gastric cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. kng4@partners.org
18. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
19. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org